Cytokinetics announced on 16 November 2026 that the US Food and Drug Administration approved adding MAPLE-HCM active-comparator trial data to the Myqorzo aficamten label. The update gives academic trial teams a concrete example of comparative research entering prescribing information for an existing indication, with the label preserving an important qualification about the primary endpoint.
FDA clears comparative evidence for the existing label
The company said its supplemental New Drug Application was approved to incorporate the trial comparing aficamten with the beta blocker metoprolol, each used as monotherapy. The development adds evidence to the label for an already approved medicine. Cytokinetics reported the decision in its 16 November announcement.
GSM Global’s report described the change as the addition of head-to-head evidence without a new indication. Investing.com’s account of the company’s UBS conference appearance also reported the inclusion of MAPLE-HCM data in the label. These reports place the development in the continuing evidence programme for Myqorzo.
What the updated prescribing information says
The November 2026 US prescribing information describes MAPLE-HCM as a randomized, double-blind, double-dummy study in 175 adults with symptomatic obstructive hypertrophic cardiomyopathy. It retains the indication for adults with symptomatic obstructive HCM to improve functional capacity and symptoms.
The primary endpoint was change in peak oxygen uptake from baseline to week 24. The label says the endpoint was met, while explicitly qualifying its interpretation: because metoprolol blunts heart rate, the interpretation and clinical meaningfulness of those results are unclear. This qualification belongs alongside the endpoint result in any account of the evidence.
For secondary outcomes, the label reports improvement of at least one New York Heart Association functional class in 51% of the aficamten group versus 26% of the metoprolol group. It also records greater improvement in patient-reported health status and reduction in the Valsalva outflow-tract gradient.
Safety remains part of the comparison. Hypertension occurred in 15% versus 3%, respectively. The label retains a boxed warning for heart failure due to systolic dysfunction and the restricted Myqorzo Risk Evaluation and Mitigation Strategy programme.
The registry explains the comparison behind the result
The ClinicalTrials.gov record for NCT05767346 identifies a parallel-group phase 3 study. Each group received its assigned active medicine and a placebo matching the other medicine. The record specifies masking of participants, investigators and outcome assessors. That detail helps explain the double-dummy design: the presence of matching placebo products supported a comparison between active treatments.
The registered primary outcome used cardiopulmonary exercise testing to measure peak oxygen uptake. Secondary outcomes covered functional class, patient-reported health status, cardiac imaging measures and a cardiac biomarker. These are distinct measurements, rather than interchangeable descriptions of a single benefit. The registry therefore supplies useful context for readers comparing the trial’s endpoint structure with the narrower selection of results presented in the label.
How this differs from the original approval evidence
The FDA’s original Myqorzo Drug Trials Snapshot gives an approval date of 19 December 2025. It describes SEQUOIA-HCM, a randomized, double-blind, placebo-controlled study involving 282 adults. Its primary endpoint also assessed change in peak oxygen uptake at week 24 through exercise testing.
The comparator is the important distinction for research interpretation: SEQUOIA-HCM used placebo, while MAPLE-HCM compared active medicines. The FDA snapshot expressly limits its account to the original approval. It provides historical context for the new label material, rather than documentation of this supplemental decision. CASRAI’s guide to clinical trial phases explains the development framework behind these phase 3 studies.
Cytokinetics emphasizes the value of comparator evidence
In the announcement, Cytokinetics president and chief executive Robert I. Blum emphasized rigorous comparative evidence as information for treatment decisions. His comments reflected the sponsor’s assessment of why bringing MAPLE-HCM into the label matters. The approved prescribing information supplies the specific results and qualifications against which that assessment can be read.
What research teams can learn from the label update
Analysis: For university trial teams, this case highlights the value of keeping the research question attached to the regulatory summary. A useful evidence account identifies the comparator, distinguishes monotherapy from background treatment, states who was studied and retains the endpoint definition. Omitting those features can make a specific trial answer appear broader than the study was designed to support.
The label’s primary-endpoint qualification is especially relevant to scientific communication. Statistical success and regulatory interpretation are separate parts of the record. A research-office briefing can describe both in the same paragraph, allowing readers to see the result and its stated interpretive boundary together. This is an editorial documentation lesson, rather than a new institutional obligation.
Teams preparing summaries can also distinguish the indication from the clinical-studies section. Adding comparative evidence to prescribing information does not, by itself, describe a newly authorized population. CASRAI’s explanation of FDA prescription-drug labeling structure provides background for that distinction, while its comparison of drug application pathways explains the wider submission context.
The next step is using the completed evidence record
The registry lists MAPLE-HCM as completed and records results first posted on 9 June 2026. With the November label now incorporating the comparison, the research communication task is to connect the study record, its outcome definitions and the approved wording. For academic teams discussing this development, that connection keeps the meaning of the label addition precise.
Sources
- Cytokinetics: Prescribing Information for Myqorzo Expanded to Include MAPLE-HCM Data, 16 November 2026, checked 2026-11-17.
- Cytokinetics: Myqorzo US Prescribing Information, revised November 2026, checked 2026-11-17.
- ClinicalTrials.gov: MAPLE-HCM, NCT05767346, public study record, checked 2026-11-17.
- FDA: Drug Trials Snapshots: Myqorzo, original approval background, checked 2026-11-17.
- GSM Global: FDA Approves Myqorzo Label Update, MAPLE-HCM Data Added, 16 November 2026, checked 2026-11-17.
- Investing.com: Cytokinetics at UBS Global Biopharma Conference 2026, 16 November 2026, checked 2026-11-17.







